Progressive Pulmonary Fibrosis
14
9
11
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 55/100
7.1%
1 terminated out of 14 trials
0.0%
-86.5% vs benchmark
36%
5 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (14)
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial
Evaluating the Efficacy and Safety of of HSK44459 in People With Progressive Pulmonary Fibrosis
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.
Xenon MRI and Progressive ILD
SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers
A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications
PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis